Off Patent Cancer Drug Shows Promise for Herpes Simplex 1

Researchers from the University of Illinois, Chicago report that doxorubicin, a long-established most cancers drug, can block the herpes simplex virus type 1 (HSV-1) in laboratory fashions and in mice. Their findings recommend we would see a brand new remedy possibility alongside current antivirals, like acyclovir, on the cabinets, however not simply but. This drug has just a few hurdles to leap earlier than it is prepared for medical use in opposition to the herpes virus.

Most individuals carry the Herpes Simplex virus with out figuring out it. For the bulk, it stays quiet, often surfacing as a chilly sore or staying hidden solely. For most cancers sufferers, transplant recipients and others whose immune methods are compromised, nonetheless, the identical virus may cause sight-threatening eye infections, mind irritation and in extreme instances, demise.

Study chief Deepak Shukla, a virologist at UIC’s College of Medicine defined in a press launch.

‘This opens up an sudden, probably fast-moving path towards treating drug-resistant herpes infections…HSV-1 infections have severe, typically life-threatening penalties, and this drug could assist save lives.‘

A brand new hope for Herpes?

For forty years, medical doctors have had principally one device to handle it: a household of antiviral medication led by acyclovir. Now a workforce on the University of Illinois, Chicago has discovered {that a} second device, one already sitting in hospital pharmacies, may work too.

The drug is doxorubicin (AKA Adriamycin), a chemotherapy medicine used to deal with breast most cancers, lymphoma, and different cancers for the reason that Sixties. In a research printed this January within the journal Drug Resistance Updates, the UIC workforce confirmed that doxorubicin can block Herpes Simplex Virus sort 1 (HSV-1) from infecting and replicating in human cells, pig corneal tissue, and mice; together with uncommon strains of the virus that not reply to acyclovir.

Why a most cancers drug? The brief reply is that it got here up in a pc search. In 2024, Shukla’s lab constructed a digital screening device known as HerpDockwhich combs by the libraries of recognized chemical compounds and flags those that is likely to be efficient in opposition to herpes.

Off patent, on course

When HerpDock highlighted doxorubicin, the workforce took discover. Not simply because it labored within the simulation, however as a result of it was already authorized by the FDA.

‘‘We have been excited after we realized that doxorubicin is already FDA-approved,’ stated Shukla. ‘That issues as a result of its security profile and dosage are already effectively understood. This drug might attain clinicians and sufferers a lot quicker than a brand-new discovery.’

That is a much bigger deal than it would sound. Getting a brand new drug from a laboratory outcomes to a pharmacist’s shelf usually takes over a decade and prices billions of {dollars}. An current authorized drug skips a lot of that queue.

Locking out unwelcome visitors

Current herpes antivirals like acyclovir work by concentrating on the virus immediately. This means they gum up the equipment the virus makes use of to repeat its DNA. That technique has labored effectively for a long time, but it surely means the medication are solely efficient so long as the virus would not change sufficient to work round them and for individuals with compromised immune methods, an extended and powerful course of acyclovir relations can take a toll.

Doxorubicin takes a distinct method. Rather than going after the virus itself, it blocks a signaling pathway inside human cells, a series of molecular switches known as PI3K-AKT-mTOR, that HSV-1 must get inside cells and begin replicating. Think of it like altering the locks on the door the virus makes use of to interrupt in, relatively than attempting to cease the virus in transit.

Since this pathway is a part of the host cell relatively than the virus, it’s a lot tougher for the virus to evolve round it. That is partly why the drug labored efficiently in opposition to acyclovir-resistant strains within the research; strains that present medication merely can not contact.

Evidential inquiries

While Herpdock recognized doxorubicin’s potential, Shukla’s workforce nonetheless needed to verify that the drug might actually block herpes infections. These early phases of proof gathering passed off within the laboratory. This was not a medical trial; no individuals have been concerned.

The workforce labored by three ranges of testing, every step extra advanced than the final.

First, they examined doxorubicin in human cells in a dish within the lab, together with corneal cells and most cancers cell traces. The drug persistently decreased the variety of virus particles that might replicate and did so at concentrations a lot decrease than these used for most cancers remedy. This issues as a result of the principle concern with doxorubicin is its toxicity at excessive doses.

Second, they used pig corneas, contaminated with HSV 1– a mannequin that carefully mimics human eye infections. The drug once more reduce viral ranges considerably, significantly when mixed with trifluridine, the usual eye drop antiviral.

Third, mice contaminated with HSV-1 within the eye have been handled topically with doxorubicin eye drops. Viral ranges within the eyes dropped, corneal injury was decreased, and crucially, there have been no indicators of drug-related toxicity to the center, blood cells, or surrounding tissue, which is the usual concern with systemic doxorubicin.

The doses utilized in these eye-drop experiments have been roughly 3,000 occasions decrease than the focus of trifluridine utilized in normal remedy, they usually achieved comparable outcomes.

The acyclovir connection

One of the research’s extra sensible findings was what occurred when doxorubicin and current antivirals got collectively. The mixture produced outcomes effectively past what both drug managed alone. In some cell-culture experiments, pairing the 2 decreased viral load by lots of to hundreds of occasions greater than both drug by itself.

This issues as a result of acyclovir, taken long-term and on the doses typically required in immunocompromised sufferers, can injury the kidneys. If a small quantity of doxorubicin permits the identical viral suppression with a decrease acyclovir dose, that might scale back the chance for sufferers who want sustained remedy.

‘I loved being part of one thing that may actually assist individuals,’ stated Divya Kapoor, a graduate scholar researcher and co-author on the research. ‘This discovery has the potential to stop herpes-related deaths and enhance affected person outcomes all over the world, together with for most cancers sufferers who use doxorubicin.’

The closing stretch

The researchers are clear that extra work is required earlier than this turns into a remedy possibility. The subsequent step shall be human medical trials, which take time to design, fund, and run. But as a result of doxorubicin is already authorized, the security groundwork has largely been laid, which generally removes years from the method.

The individuals almost definitely to learn first are these whose immune methods are already compromised. Chemotherapy sufferers particularly face a well-documented threat of herpes reactivation. The virus, which lies dormant in nerve tissue in most adults, can flare up when the immune system is suppressed. The researchers level out that some most cancers sufferers already receiving doxorubicin is likely to be getting some inadvertent safety in opposition to this, a query price investigating.

For the final inhabitants with recurrent chilly sores or genital herpes, a topical doxorubicin product (an eye fixed drop or cream, for occasion) is a extra believable near-term utility. The drug wouldn’t have to flow into by the entire physique at cancer-chemotherapy ranges to be helpful.

An outdated most cancers drug, a brand new drug for Herpes

HSV-1 infects an estimated 4 billion individuals worldwide, in accordance with the World Health Organization, making it probably the most frequent viral infections in existence. It can be the main infectious reason behind blindness globally. A brand new remedy possibility, significantly one which works by a mechanism the virus can not simply evolve round, would fill a niche that has been open for a very long time.

References

Sharma P, et al. (2026). Host-directed novel mechanistic insights of doxorubicin reveal its efficacy in opposition to drug-resistant HSV-1 underscoring dangers with oncolytic virotherapy. Drug Resistance Updates, 86, 101362. https://doi.org/10.1016/j.drup.2026.101362

University of Illinois Chicago/EurekAlert press launch (March 24, 2026): ‘UIC analysis: A most cancers drug that treats herpes, too.’ https://www.eurekalert.org/news-releases/1121079

World Health Organization (2023). Herpes simplex virus. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus

Sandherr M, et al. (2006). Antiviral prophylaxis in sufferers with haematological malignancies and strong tumors. Annals of Oncology, 17(7), 1051–1059. [Re: HSV reactivation risk during chemotherapy – cited in primary paper]

Kapoor D, Sharma P, Shukla D (2024). Emerging medication for the remedy of herpetic keratitis. Expert Opinion on Emerging Drugs, 29(2), 113–126. [HerpDock tool – cited in primary paper]